Efficacy of Tuberculosis Vaccine Candidate pcDNA3.1-rpfB in Inhibiting the Growth of Mycobacterium tuberculosis In Vitro with Mycobacterial Growth Inhibition Assay

Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb). Bacille Calmette-Guérin (BCG) the only licensed vaccine against TB, and it effective in children but not adults. The Vaccine Research Team, Department of Microbiology FKUI has developed a DNA-based TB candidate pcDNA3.1-rpfB. This induces immune responses mice, its potency unknown. gold standard for testing challenge method. BSL3 animal laboratory method currently unavailable at FKUI. Therefore, mycobacterial growth inhibition assay (MGIA) was used as preliminary test before vivo conducted. principle MGIA to reculture Mtb Mycobacteria Growth Indicator Tube (MGITTM) from co-cultured with mammalian cells that have been previously treated pcDNA3.1-rpfB, pcDNA3.1 (negative control), BCG (positive control). MGITTM shows time positivity, which lapsed until positive detected. In addition, measurements interferon (IFN)γ levels enzyme-linked immunosorbent were carried out. study concluded pcDNA3.1-rpfB can inhibit vitro showed no statistical difference BCG. IFNγ co-culturing did correlate level vitro.